Autoimmune Diseases
Otsuka Seeks Accelerated Approval for Sibeprenlimab in IgA Nephropathy Following Positive Phase III Interim Results
Otsuka, sibeprenlimab, IgA nephropathy, Phase III trial, accelerated approval, FDA, kidney disease, autoimmune disease, APRIL antibody.
IGM Biosciences Undergoes Strategic Pivot to Autoimmune Diseases, Overhauls Leadership and Reduces Workforce
IGM Biosciences, autoimmune diseases, strategic pivot, T cell-engaging IgM antibodies, leadership changes, workforce reduction, imvotamab, IGM-2644
IGM Biosciences Shifts Focus to Autoimmune Diseases Amid Leadership Changes
IGM Biosciences, autoimmune diseases, C-suite exits, biotechnology, immunology, arthritis, lupus
Roche’s Gazyva Shows Promising Results in Phase 3 Lupus Nephritis Trial, Paving Way for Expanded Use
Gazyva, lupus nephritis, Roche, phase 3 trial, REGENCY study, obinutuzumab, kidney disease, autoimmune disease, treatment options.
Gazyva Shows Promising Results in Lupus Nephritis Treatment, Paving Way for Expanded Indication
Gazyva, lupus nephritis, Roche, Genentech, Phase III REGENCY study, complete renal response, autoimmune disease, kidney function, end-stage kidney disease.
AstraZeneca Secures FDA Approval for Fasenra in Rare Autoimmune Disorder EGPA
AstraZeneca, Fasenra, FDA approval, EGPA, rare autoimmune disorder, asthma biologic
AstraZeneca’s Fasenra Gains FDA Approval for Eosinophilic Granulomatosis with Polyangiitis, Expanding Treatment Options for Rare Autoimmune Disease
AstraZeneca, Fasenra, FDA approval, eosinophilic granulomatosis with polyangiitis (EGPA), rare autoimmune disease, biologic treatment, asthma medication, GSK’s Nucala
Dupixent (Dupilumab) Shows Promising Results in Treating Bullous Pemphigoid, Paving Way for Regulatory Submissions
Dupixent, Dupilumab, Bullous Pemphigoid, Autoimmune Disease, Biologic Treatment, Type 2 Inflammation
Adicet Bio Expands into Autoimmune Diseases with Allogeneic Gamma Delta T Cell Therapy
Adicet Bio, Autoimmune diseases, Allogeneic gamma delta T cell therapy, Lupus nephritis, Systemic lupus erythematosus (SLE), Cell therapy
Candid Therapeutics Launches with $370 Million Funding, Aims to Revolutionize T Cell Engager Market for Autoimmune Diseases
Candid Therapeutics, T Cell Engager, Autoimmune Diseases, Biotech Funding, Ken Song, Pharmaceutical Industry